检索范围:
排序: 展示方式:
《医学前沿(英文)》 2022年 第16卷 第2期 页码 285-294 doi: 10.1007/s11684-021-0843-8
关键词: CAR-T cell therapy refractory diffuse large B-cell lymphoma cytokine release syndrome dose-limiting toxicity
《医学前沿(英文)》 2023年 第17卷 第4期 页码 699-713 doi: 10.1007/s11684-022-0972-8
关键词: anti-CD19 chimeric antigen receptor T immunotherapy diffuse large B cell lymphoma tumor microenvironment tumor-associated macrophage metabolism
《医学前沿(英文)》 页码 889-906 doi: 10.1007/s11684-023-0994-x
关键词: primary central nervous system lymphoma whole-genome sequencing TMSB4X copy number variation gene mutation
Primary spinal epidural non-Hodgkin’s lymphoma presented with spinal cord compression syndrome
Chunquan CAI MD, PhD, Qingjiang ZHANG BM, Changhong SHEN MD, PhD,
《医学前沿(英文)》 2009年 第3卷 第4期 页码 499-502 doi: 10.1007/s11684-009-0075-9
关键词: non-Hodgkin’ s lymphoma primary spinal cord compression syndrome epidural space
Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 786-791 doi: 10.1007/s11684-020-0751-3
关键词: anti-CD19 chimeric antigen receptor T cell soft tissue bone marrow relapsed or refractory non-Hodgkin lymphoma
Expression and bioinformatic analysis of lymphoma-associated novel gene KIAA0372
BAI Xiangyang, TANG Duozhuang, ZHU Tao, SUN Lishi, YAN Lingling, LU Yunping, ZHOU Jianfeng, MA Ding
《医学前沿(英文)》 2007年 第1卷 第1期 页码 93-98 doi: 10.1007/s11684-007-0018-2
关键词: bioinformatic analysis functional KIAA0372 detection Microarray
Maura Massimino, Marta Podda, Lorenza Gandola, Emanuele Pignoli, Ettore Seregni, Carlo Morosi, Filippo Spreafico, Andrea Ferrari, Emilia Pecori, Monica Terenziani
《医学前沿(英文)》 2021年 第15卷 第1期 页码 101-107 doi: 10.1007/s11684-020-0752-2
关键词: iatrogenic primary hypothyroidism late effects of radiotherapy long-term follow-up medulloblastoma Hodgkin lymphoma
Therapeutic effects of thalidomide in hematologic disorders: a review
null
《医学前沿(英文)》 2013年 第7卷 第3期 页码 290-300 doi: 10.1007/s11684-013-0277-z
The extensive autoimmune, anti-inflammatory, and anticancer applications of thalidomide have inspired a growing number of studies and clinical trials. As an inexpensive agent with relatively low toxicity, thalidomide is regarded as a promising therapeutic candidate, especially for malignant diseases. We review its therapeutic effects in hematology, including those on multiple myeloma, Waldenstroem macroglobulinemia, lymphoma, mantle-cell lymphoma, myelodysplastic syndrome, hereditary hemorrhagic telangiectasia, and graft-versus-host disease. Most studies have shown satisfactory results, although several have reported the opposite. Aside from optimal outcomes, the toxicities and adverse effects of thalidomide should also be examined. The current work includes a discussion of the mechanisms through which the novel biological effects of thalidomide occur, although more studies should be devoted to this aspect. With appropriate safeguards, thalidomide may benefit patients suffering from a broad variety of disorders, particularly refractory and resistant diseases.
Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock
null
《医学前沿(英文)》 2014年 第8卷 第2期 页码 254-258 doi: 10.1007/s11684-014-0319-1
Mantle cell lymphoma is an aggressive subtype of B cell non-Hodgkin lymphoma. It can progress to leukemic phase but frank leukemic picture at initial presentation is not common. Leukemic phase indicates advance stage of the disease and generally associated with extensive extra-nodal involvement. Pericardial invasion has been reported, however we could not find a report of myocardial infiltration by this disease since the appraisal of the term “mantle cell lymphoma” in 1992. Here we report a case of cardiac involvement by mantle cell leukemia leading to cardiogenic shock which complicates the treatment decisions.
Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)
《医学前沿(英文)》 2022年 第16卷 第5期 页码 815-826 doi: 10.1007/s11684-021-0891-0
关键词: B-cell lymphoma oral drug targeted therapy immunotherapy COVID-19 pandemic
null
《医学前沿(英文)》 2018年 第12卷 第3期 页码 324-329 doi: 10.1007/s11684-017-0558-z
Splenic lymphoma with villous lymphocytes (SLVL) or splenic marginal zone lymphoma with circulating villous lymphocytes is rare, and prolymphocytic transformation of SLVL is rarer. At present, only one case of SLVL with t(8;14)(q24;q32) translocation has been reported. In this study, we report a case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) chromosome translocation that we inclined to SLVL with a prolymphocytic transformation. A 73-year-old female showed marked hepatosplenomegaly and high lymphocytosis (lymphocytes>200×109/L). The abnormal lymphocytes had short coarse villi and round nuclei with prominent nucleoli. The immunophenotypes showed CD19+, CD20+, HLA-DR+, CD22+, CD5+, Kappa+, CD25dim, CD71dim, Lambda−, CD7−, CD10−, CD23−, CD34−, CD33−, CD13−, CD14−, CD117−, CD64−, CD103−, and CD11c−. The karyotype showed complex abnormality: 46XX,+3,−10, t(8;14)(q24;q32)[11]/46XX[9]. The cytoplasmic projection, immunological characteristics, and trisomy 3 chromosome abnormality supported the diagnosis of SLVL. However, the presence of prominent nucleoli and high lymphocytosis suggested prolymphocytic transformation, probably as a result of t(8,14) chromosome translocation. In this report, we described an unusual case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation, which could provide help in the diagnosis and differential diagnosis of B-lymphocytic proliferative diseases.
关键词: splenic lymphoma with villous lymphocytes splenic marginal zone lymphoma transformation chromosome translocation
Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells
null
《医学前沿(英文)》 2018年 第12卷 第4期 页码 374-386 doi: 10.1007/s11684-018-0652-x
A family of transcription factors known as Id proteins, or inhibitor of DNA binding and differentiation, is capable of regulating cell proliferation, survival and differentiation, and is often upregulated in multiple types of tumors. Due to their ability to promote self-renewal, Id proteins have been considered as oncogenes, and potential therapeutic targets in cancer models. On the contrary, certain Id proteins are reported to act as tumor suppressors in the development of Burkitt’s lymphoma in humans, and hepatosplenic and innate-like T cell lymphomas in mice. The contexts and mechanisms by which Id proteins can serve in such contradictory roles to determine tumor outcomes are still not well understood. In this review, we explore the roles of Id proteins in lymphocyte development and tumorigenesis, particularly with respect to inhibition of their canonical DNA binding partners known as E proteins. Transcriptional regulation by E proteins, and their antagonism by Id proteins, act as gatekeepers to ensure appropriate lymphocyte development at key checkpoints. We re-examine the derailment of these regulatory mechanisms in lymphocytes that facilitate tumor development. These mechanistic insights can allow better appreciation of the context-dependent roles of Id proteins in cancers and improve considerations for therapy.
关键词: Id proteins lymphoma leukemia T cells B cells tumor suppressor oncogene
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 711-725 doi: 10.1007/s11684-020-0808-3
关键词: chimeric antigen receptor T (CAR-T) cell lymphoma cytokine release syndrome (CRS) immune effector cell-associated neurotoxicity syndrome (ICANS)
Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang
《医学前沿(英文)》 2020年 第14卷 第6期 页码 811-815 doi: 10.1007/s11684-020-0740-6
关键词: anti-CD19 chimeric antigen receptor T cells mantle cell lymphoma relapsed or refractory long-term follow-up
Yiwen Cao, Zhenhua Liu, Wen Wu, Ying Qian, Qin Shi, Rong Shen, Binshen Ouyang, Pengpeng Xu, Shu Cheng, Jin Ye, Yiming Lu, Chaofu Wang, Chengde Yang, Li Wang, Weili Zhao
《医学前沿(英文)》 2019年 第13卷 第1期 页码 94-103 doi: 10.1007/s11684-019-0680-1
Autoimmune diseases (ADs) increase the risk of non-Hodgkin’s lymphoma and contribute to poor prognosis of patients. However, the association between immunologic markers and clinical outcome has rarely been investigated. This study aims to analyze the prognostic value of pretreatment immunologic markers in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). We retrospectively reviewed the data on 502 patients with DLBCL treated in our institution from January 2013 to March 2018. Survival functions were estimated using Kaplan–Meier method and Cox regression model. The 3-year progression free survival (PFS) and overall survival (OS) rates were 70.2% and 80.9%, respectively, and the complete remission (CR) rate was 78.1%. Among the patients, those with multiple (≥3) abnormal immunologic markers had significantly shorter 3-year PFS (52.7% vs. 77.3%, P<0.001) and OS (68.5% vs. 85.8%, P=0.001) than those without multiple abnormal immunologic markers. Multivariate analysis revealed that the presence of multiple abnormal immunologic markers and the elevated serum levels of lactate dehydrogenase were the independent adverse prognostic factors for PFS (P=0.008, P<0.001) and OS (P=0.003, P<0.001). Meanwhile, advanced Ann Arbor stage was an independent adverse prognostic factor for PFS (P=0.001) and age>60 years for OS (P=0.014). In conclusion, the immunologic status was closely related to lymphoma progression, and this study provides new insights into the risk stratification of patients with DLBCL.
关键词: immunologic marker diffuse large B-cell lymphoma prognosis
标题 作者 时间 类型 操作
study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma
期刊论文
Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma
期刊论文
Analysis of the genomic landscape of primary central nervous system lymphoma using whole-genome sequencing
期刊论文
Primary spinal epidural non-Hodgkin’s lymphoma presented with spinal cord compression syndrome
Chunquan CAI MD, PhD, Qingjiang ZHANG BM, Changhong SHEN MD, PhD,
期刊论文
extranodal involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma
Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang
期刊论文
Expression and bioinformatic analysis of lymphoma-associated novel gene KIAA0372
BAI Xiangyang, TANG Duozhuang, ZHU Tao, SUN Lishi, YAN Lingling, LU Yunping, ZHOU Jianfeng, MA Ding
期刊论文
thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkin lymphoma
Maura Massimino, Marta Podda, Lorenza Gandola, Emanuele Pignoli, Ettore Seregni, Carlo Morosi, Filippo Spreafico, Andrea Ferrari, Emilia Pecori, Monica Terenziani
期刊论文
Chinese expert consensus on oral drugs for the treatment of mature B-cell lymphomas (2020 edition)
期刊论文
A rare case of B-lymphoproliferative disorder with villous lymphocytes harboring t(8;14)(q24;q32) translocation
null
期刊论文
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang
期刊论文
antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma
Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang
期刊论文